Institution
Hospital General Universitario Gregorio Marañón
Healthcare•Madrid, Spain•
About: Hospital General Universitario Gregorio Marañón is a healthcare organization based out in Madrid, Spain. It is known for research contribution in the topics: Population & Transplantation. The organization has 11975 authors who have published 12386 publications receiving 244847 citations.
Topics: Population, Transplantation, Medicine, Myocardial infarction, Cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Infection with C. difficile imposes a significant burden not only on patients, owing to increased morbidity and mortality, but also on healthcare systems and society in general, and measures to more effectively prevent CDI and reduce CDI recurrence rates may help to reduce this burden.
207 citations
••
VU University Medical Center1, University of Cambridge2, University of Düsseldorf3, Peter MacCallum Cancer Centre4, St James's University Hospital5, University of Pavia6, Hospital General Universitario Gregorio Marañón7, University of Göttingen8, University Hospitals Bristol NHS Foundation Trust9, Erasmus University Rotterdam10, University of Salamanca11, Radboud University Nijmegen12, Nippon Medical School13, Karolinska University Hospital14, Medical University of Vienna15, Nancy-Université16
TL;DR: The working group is dedicated to initiate further studies to establish robust diagnostic and prognostic FC panels in MDS and stresses that FC should be part of an integrated diagnosis rather than a separate technique.
Abstract: Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as 'normal', 'suggestive of', or 'diagnostic of' MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced. The working group is dedicated to initiate further studies to establish robust diagnostic and prognostic FC panels in MDS. An ultimate goal is to refine and improve diagnosis and prognostic scoring systems. Finally, the working group stresses that FC should be part of an integrated diagnosis rather than a separate technique.
207 citations
••
TL;DR: The CheckMate 511 study met its primary end point, demonstrating a significantly lower incidence of treatment-related grade 3-5 AEs with NIVO3+IPI1 versus NIVo1+IPi3, and no meaningful differences between the groups for any efficacy end point.
Abstract: PURPOSENivolumab 1 mg/kg plus ipilimumab 3 mg/kg (NIVO1+IPI3) is approved for first-line treatment of patients with advanced melanoma in several countries. We conducted a phase IIIb/IV study (CheckMate 511) to determine if nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (NIVO3+IPI1) improves the safety profile of the combination.PATIENTS AND METHODSPatients (N = 360) age 18 years or older with previously untreated, unresectable stage III or IV melanoma were randomly assigned 1:1 to NIVO3+IPI1 or NIVO1+IPI3 once every 3 weeks for four doses. After 6 weeks, all patients received NIVO 480 mg once every 4 weeks until disease progression or unacceptable toxicity. The primary end point was a comparison of the incidence of treatment-related grade 3 to 5 adverse events (AEs) between groups. Secondary end points included descriptive analyses of objective response rate, progression-free survival, and overall survival. The study was not designed to formally demonstrate noninferiority of NIVO3+IPI1 to NIVO1+IPI3 for effica...
207 citations
••
TL;DR: Scedosporium prolificans is an emerging multiresistant fungal pathogen that may cause asymptomatic colonization, localized infection related to trauma or surgery, and rapidly fatal disseminated infection in immunocompromised hosts, particularly those with neutropenia.
206 citations
••
TL;DR: Tacrolimus is a very useful therapeutic option for patients with membranous nephropathy and preserved renal function and the majority of patients experienced remission with a significant reduction in the risk for deteriorating renal function.
205 citations
Authors
Showing all 12014 results
Name | H-index | Papers | Citations |
---|---|---|---|
David H. Adams | 155 | 1613 | 117783 |
Stefanie Dimmeler | 147 | 574 | 81658 |
Stuart J. Pocock | 145 | 684 | 143547 |
M. I. Martínez | 134 | 1251 | 79885 |
Guy A. Rouleau | 129 | 884 | 65892 |
Jose L. Jimenez | 124 | 654 | 64226 |
Antoni Torres | 120 | 1238 | 65049 |
Paul P. Tak | 112 | 591 | 57689 |
Luis A. Diaz | 111 | 596 | 75036 |
Frans Van de Werf | 109 | 747 | 63537 |
José Luis Zamorano | 105 | 695 | 133396 |
Francisco Sánchez-Madrid | 102 | 527 | 43418 |
Francesco Locatelli | 99 | 820 | 42454 |
Roberto M. Lang | 96 | 823 | 56638 |
Carlos Simón | 95 | 589 | 31147 |